Cancer type

Other / multiple

Updates that span more than one tumor type, including pan-cancer MRD studies and multi-indication coverage decisions.

Jan 1, 2026Other MRD / ctDNA Reimbursement / coverage

MolDX lists two assays for monitoring response to immune-checkpoint inhibitor therapy

The MolDX billing article A58434, in the revision effective January 1, 2026, lists Signatera for monitoring response to immune-checkpoint inhibitor therapy in advanced solid tumors and Guardant Response for inoperable or metastatic solid tumors.

CMS MolDX

ASCO 2025Other MRD / ctDNA Conference data Tumor-informed

MONSTAR-SCREEN-3 preliminary cohort detected baseline ctDNA across 15 solid-tumor types

An ASCO 2025 preliminary report from MONSTAR-SCREEN-3, with 114 patients across 15 cancer types as of December 2024, found baseline ctDNA in 41 of 41 tested patients and postoperative month-1 MRD positivity in 10 of 28, including colorectal, gastric, head and neck, renal cell, esophageal, and pancreatic cancers.

Journal of Clinical Oncology